These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35772229)

  • 1. The Outcome of COVID-19 in Pediatric-Onset Multiple Sclerosis Patients.
    Oncel I; Alici N; Solmaz I; Oge DD; Ozsurekci Y; Anlar B
    Pediatr Neurol; 2022 Sep; 134():7-10. PubMed ID: 35772229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis.
    Louapre C; Collongues N; Stankoff B; Giannesini C; Papeix C; Bensa C; Deschamps R; Créange A; Wahab A; Pelletier J; Heinzlef O; Labauge P; Guilloton L; Ahle G; Goudot M; Bigaut K; Laplaud DA; Vukusic S; Lubetzki C; De Sèze J; ; Derouiche F; Tourbah A; Mathey G; Théaudin M; Sellal F; Dugay MH; Zéphir H; Vermersch P; Durand-Dubief F; Françoise R; Androdias-Condemine G; Pique J; Codjia P; Tilikete C; Marcaud V; Lebrun-Frenay C; Cohen M; Ungureanu A; Maillart E; Beigneux Y; Roux T; Corvol JC; Bordet A; Mathieu Y; Le Breton F; Boulos DD; Gout O; Guéguen A; Moulignier A; Boudot M; Chardain A; Coulette S; Manchon E; Ayache SS; Moreau T; Garcia PY; Kumaran D; Castelnovo G; Thouvenot E; Taithe F; Poupart J; Kwiatkowski A; Defer G; Derache N; Branger P; Biotti D; Ciron J; Clerc C; Vaillant M; Magy L; Montcuquet A; Kerschen P; Coustans M; Guennoc AM; Brochet B; Ouallet JC; Ruet A; Dulau C; Wiertlewski S; Berger E; Buch D; Bourre B; Pallix-Guiot M; Maurousset A; Audoin B; Rico A; Maarouf A; Edan G; Papassin J; Videt D
    JAMA Neurol; 2020 Sep; 77(9):1079-1088. PubMed ID: 32589189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Simpson-Yap S; De Brouwer E; Kalincik T; Rijke N; Hillert JA; Walton C; Edan G; Moreau Y; Spelman T; Geys L; Parciak T; Gautrais C; Lazovski N; Pirmani A; Ardeshirdavanai A; Forsberg L; Glaser A; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton R; Salter A; Fox RJ; van der Walt A; Butzkueven H; Alroughani R; Ozakbas S; Rojas JI; van der Mei I; Nag N; Ivanov R; Sciascia do Olival G; Dias AE; Magyari M; Brum D; Mendes MF; Alonso RN; Nicholas RS; Bauer J; Chertcoff AS; Zabalza A; Arrambide G; Fidao A; Comi G; Peeters L
    Neurology; 2021 Nov; 97(19):e1870-e1885. PubMed ID: 34610987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Safavi F; Nourbakhsh B; Azimi AR
    Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
    Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis.
    Baroncini D; Simone M; Iaffaldano P; Brescia Morra V; Lanzillo R; Filippi M; Romeo M; Patti F; Chisari CG; Cocco E; Fenu G; Salemi G; Ragonese P; Inglese M; Cellerino M; Margari L; Comi G; Zaffaroni M; Ghezzi A;
    JAMA Neurol; 2021 Jun; 78(6):726-735. PubMed ID: 33938921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of SARS-CoV-2 Infection in Unvaccinated Multiple Sclerosis Patients on Disease-Modifying Therapies.
    Al-Shammri S; Chadha G; Chattopadhyay A; Doi S
    Med Princ Pract; 2023; 32(2):143-148. PubMed ID: 37231972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease-modifying therapies, outcomes, risk factors and severity of COVID-19 in multiple sclerosis: A MENACTRIMS registry based study.
    Zeineddine M; Al-Hajje A; Salameh P; Massouh J; Saab G; Al-Roughani R; Ahmed SF; Al-Mahdawi A; Shalaby N; Inshasi J; Sahraian MA; Gouider R; Mrabet S; Al-Khabouri J; Shayganneja V; Chentouf A; Boumediene F; Yamout B
    Mult Scler Relat Disord; 2024 Oct; 90():105790. PubMed ID: 39121598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune responses following COVID-19 infection in multiple sclerosis patients using immunomodulatory therapy.
    Bilge N; Kesmez Can F; Yevgi R
    Acta Neurol Belg; 2023 Oct; 123(5):1885-1892. PubMed ID: 36331727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What an adult multiple sclerosis registry can tell us about pediatric onset multiple sclerosis?
    Alkolfat F; Said S; Mekky J; Eldeeb H
    Mult Scler Relat Disord; 2023 Nov; 79():104962. PubMed ID: 37714097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review.
    Sharifian-Dorche M; Sahraian MA; Fadda G; Osherov M; Sharifian-Dorche A; Karaminia M; Saveriano AW; La Piana R; Antel JP; Giacomini PS
    Mult Scler Relat Disord; 2021 May; 50():102800. PubMed ID: 33578206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia.
    Seery N; Li V; Nguyen AL; Roos I; Buzzard KA; Atvars R; Taylor N; Tunnell K; Carey J; Dwyer C; Taylor HFL; Baker J; Marriott MP; Kilpatrick TJ; Kalincik T; Monif M
    Mult Scler Relat Disord; 2020 Nov; 46():102516. PubMed ID: 32957057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.
    Mallucci G; Zito A; Baldanti F; Gastaldi M; Fabbro BD; Franciotta D; Bergamaschi R
    Mult Scler Relat Disord; 2021 Apr; 49():102754. PubMed ID: 33609958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran.
    Paybast S; Hejazi SA; Molavi P; Habibi MA; Naser Moghadasi A
    Mult Scler Relat Disord; 2022 Apr; 60():103712. PubMed ID: 35247752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of pediatric patients with multiple sclerosis and related disorders infected with SARS-CoV-2.
    Schreiner T; Wilson-Murphy M; Mendelt-Tillema J; Waltz M; Codden R; Benson L; Gorman M; Goyal M; Krupp L; Lotze T; Mar S; Ness J; Rensel M; Roalstad S; Rodriguez M; Rose J; Shukla N; Waubant E; Wheeler Y; Casper TC; Chitnis T
    Mult Scler; 2023 Apr; 29(4-5):576-584. PubMed ID: 36960480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
    Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
    Front Immunol; 2022; 13():868915. PubMed ID: 35432335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England.
    Garjani A; Patel S; Bharkhada D; Rashid W; Coles A; Law GR; Evangelou N
    Mult Scler Relat Disord; 2022 Jan; 57():103458. PubMed ID: 34896876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia.
    Stastna D; Menkyova I; Drahota J; Mazouchova A; Adamkova J; Ampapa R; Grunermelova M; Peterka M; Recmanova E; Rockova P; Rous M; Stetkarova I; Valis M; Vachova M; Woznicova I; Horakova D
    Mult Scler Relat Disord; 2021 Sep; 54():103104. PubMed ID: 34216998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Disease-Modifying Therapies on COVID-19 Vaccination Efficacy in Multiple Sclerosis Patients: A Comprehensive Review.
    Jamali E; Shapoori S; Farrokhi MR; Vakili S; Rostamzadeh D; Iravanpour F; Tavakoli Oliaee R; Jafarinia M
    Viral Immunol; 2023; 36(6):368-377. PubMed ID: 37276047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.
    Zheng C; Kar I; Chen CK; Sau C; Woodson S; Serra A; Abboud H
    CNS Drugs; 2020 Sep; 34(9):879-896. PubMed ID: 32780300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.